About Us
Who is BioRetis GmbH?
BioRetis GmbH is an interdisciplinary group with expertise in the fields of
Medicine
-
Mathematics
-
Bioinformatics
Biology
clinical trials, biobanks and documentation.
Our research focuses are:
the analysis of
microarray gene expression data from Affymetrix-based studies
high-dimensional cytometry data from flow cytometric and mass spectrometric cell investigations
microbiome sequence data from typing sequencing
the development of
software/databases/applications for the collection of data in clinical trials
new algorithms for the exploitation of functional networks
the management of biobanks
Meet Our Experts
Rainer Seubert
Economist (VWA)
CEO | Shareholderrainer.seubert[at]bioretis.com
Till Sörensen
DIPL. MATHEMATICS
Shareholder | Head of Analysticstill.soerensen[at]bioretis.com
Sascha Johannes
M. SC. BIOINFORMATICS
Shareholder | Head of Developmentsascha.johannes[at]bioretis.com
Bettina Johannes
B. SC. MATHEMATICS
Research & Developmentbettina.johannes[at]bioretis.com
Thomas Häupl
PD DR. MED. HABIL.
Main Shareholder | Founderthomas.haeupl[at]bioretis.com
Marc Bonin-Andresen
M. SC. BIOINFORMATICS
Shareholdermarc.bonin-andresen[at]bioretis.com
Our History
2006
Company founded by PD Dr. Thomas Häupl and colleagues as a spin-off of Charité - Universitätsmedizin Berlin
Rainer Seubert as Consultant
Cooperation with Charité-Universitätsmedizin Berlin and Deutsches Rheuma Forschungszentrum for analysis of Affymetrix transcriptome data (bioinformatics)
2010
AI ImmunoClust software development in the Charité Research Group for user independent clustering of cytometry data from clinical research by members of our team
Testing and adapting to the heterogeneity of cytometry data
Development of strategies for automated cluster characterization (cell type identification) for application in Rheumatology
2016-2017
Development of adaptations for an early Cancer Screening Tests based on the AI tool immunoClust
Appointment Rainer Seubert as CEO
Long-term agreement signed with leading developer and marketing company of an early Cancer Screening Test
Development of an automated immunoClust AI-analysis pipeline for the cytometry based Cancer Screening Test
2018 to date
Analysis of cytometry data for the Cancer Screening Test in clinical studies worldwide
2020
Team Charité moves to spin off company BioRetis from Charité Universitätsmedizin Berlin
Certification (CE) of cytometry based Cancer Screening Test by project partner company
2022
New shareholder structure - PD Dr. Häupl and Team
2022 to date
Analysis of the worldwide marketed Cancer Screening Test, refinement of the iCAP tool, iCAP software adaptation for use on cloud servers for scalability, multi-user availability and flexibility for individual immune screening concepts
Certification (CE) for new cytometry tests
